CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc. ( CMT ), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction ( ED ), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing re-programmed stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities. In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz platform (CELZ-100), that utilize a patient’s own extracted immune cells that are then reprogrammed/supercharged by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties (or supercharges them) providing them with the ability to treat multiple indications.